{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:44:08Z","timestamp":1770709448392,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004522","name":"Top Institute Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004522","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bmc.2019.06.027","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:21:20Z","timestamp":1560856880000},"page":"3998-4012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors"],"prefix":"10.1016","volume":"27","author":[{"given":"Erik","family":"de Heuvel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhimanyu K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewald","family":"Edink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payman","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel P.","family":"Krell-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toine","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-3202","authenticated-orcid":false,"given":"Guy","family":"Caljon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titilola D.","family":"Kalejaiye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maikel","family":"Wijtmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry P.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-1827","authenticated-orcid":false,"given":"Geert","family":"Jan Sterk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Siderius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwan J.P.","family":"de Esch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.06.027_b0005","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2019.06.027_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human african trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2019.06.027_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/bmb\/ldp046","article-title":"Neglected tropical diseases","volume":"93","author":"Feasey","year":"2010","journal-title":"Br Med Bull"},{"key":"10.1016\/j.bmc.2019.06.027_b0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog Global Health"},{"key":"10.1016\/j.bmc.2019.06.027_b0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pt.2003.09.002","article-title":"Chemotherapy of human African trypanosomiasis: current and future prospects","volume":"19","author":"Fairlamb","year":"2003","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bmc.2019.06.027_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2007.02.004","article-title":"Drugs and drug resistance in African trypanosomiasis","volume":"10","author":"Delespaux","year":"2007","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.bmc.2019.06.027_b0035","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bmc.2019.06.027_b0040","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: current issues and challenges","volume":"113","author":"Kennedy","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmc.2019.06.027_b0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/ETLS20170113","article-title":"Drug resistance in protozoan parasites","volume":"1","author":"de Koning","year":"2017","journal-title":"Emerging Top Life Sci"},{"key":"10.1016\/j.bmc.2019.06.027_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00032","article-title":"Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei","volume":"6","author":"Munday","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.027_b0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2019.06.027_b0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2019.06.027_b0065","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.06.027_b0070","first-page":"47","article-title":"Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction","volume":"8","author":"Boolell","year":"1996","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.bmc.2019.06.027_b0075","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1096\/fj.06-6818com","article-title":"The Trypanosoma brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are essential for parasite virulence","volume":"21","author":"Oberholzer","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2019.06.027_b0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molbiopara.2005.09.018","article-title":"Cyclic nucleotide specific phosphodiesterases of the kinetoplastida: a unified nomenclature","volume":"145","author":"Kunz","year":"2006","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.bmc.2019.06.027_b0085","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.tetlet.2015.04.061","article-title":"Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)","volume":"56","author":"Amata","year":"2015","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.06.027_b0090","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1016\/j.bmcl.2014.07.063","article-title":"Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors","volume":"24","author":"Amata","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.06.027_b0095","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1021\/jm3017877","article-title":"Discovery of NovelTrypanosoma bruceiPhosphodiesterase B1 inhibitors by virtual screening against the unliganded tbrpdeb1 crystal structure","volume":"56","author":"Jansen","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0100","article-title":"Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei","author":"Ochiana","year":"2014","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2019.06.027_b0105","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.bmcl.2012.01.119","article-title":"Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.06.027_b0110","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1016\/j.bmcl.2013.08.057","article-title":"Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)","volume":"23","author":"Woodring","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.06.027_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1087057114549735","article-title":"Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits","volume":"20","author":"Blaazer","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmc.2019.06.027_b0120","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1021\/jm301059b","article-title":"Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1","volume":"55","author":"Orrling","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir857","article-title":"Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets","volume":"206","author":"de Koning","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmc.2019.06.027_b0130","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/jm010837k","article-title":"Novel selective PDE4 inhibitors. 1. synthesis, structure-activity relationships, and molecular modeling of 4-(3, 4-dimethoxyphenyl)-2 H-phthalazin-1-ones and analogues","volume":"44","author":"Van der Mey","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0135","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/jm010838c","article-title":"Novel selective PDE4 inhibitors. 2. synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones","volume":"44","author":"Van der Mey","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0140","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bmc.2016.02.032","article-title":"Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals","volume":"24","author":"Veerman","year":"2016","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0898-6568(96)00173-8","article-title":"Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases","volume":"9","author":"Souness","year":"1997","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmc.2019.06.027_b0150","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.027_b0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0026-895X(25)10530-0","article-title":"Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase","volume":"48","author":"Seldon","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.027_b0160","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.7b01670","article-title":"Targeting a subpocket in Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) enables the structure-based discovery of selective inhibitors with trypanocidal activity","author":"Blaazer","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4155\/fmc.11.77","article-title":"Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite","volume":"3","author":"Seebeck","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2019.06.027_b0170","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.tetlet.2007.11.135","article-title":"Microwave-based synthesis of novel thienopyrimidine bioisosteres of gefitinib","volume":"49","author":"Phoujdar","year":"2008","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2019.06.027_b0175","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1107\/S0907444913015308","article-title":"Decision making in xia2","volume":"69","author":"Winter","year":"2013","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S0907444909047374","article-title":"Integration, scaling, space-group assignment and post-refinement","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0185","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0200","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J Appl Crystallogr"},{"key":"10.1016\/j.bmc.2019.06.027_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr Sect D"},{"key":"10.1016\/j.bmc.2019.06.027_b0215","unstructured":"The PyMOL Molecular Graphics System, Version 1.7, Schr\u00f6dinger, LLC."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618316298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618316298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:04:40Z","timestamp":1760835880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618316298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":43,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0968089618316298"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.06.027","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}